Familial Myeloproliferative Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

17 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-03-31

Study Completion Date

2015-06-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Myeloproliferative disorders occur in families, thus giving rise to the theory that it is a genetic disease that may be caused by an abnormal gene in the DNA that can be passed from one generation of family members to another. DNA can be gathered from family members through blood samples and the investigators will investigate (through DNA testing) to see if there are abnormal genes that may be responsible for causing the MPDs. Understanding which genes are responsible for causing MPDs can help develop ways to identify people who may be at risk for developing an MPD, allow for the development of better treatments, possibly a cure, or even prevent the development of MPDs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes

NCT00715247

Polycythemia Vera Essential Thrombocythemia Myelofibrosis

COMPLETED

Investigation of the Genetics of Hematologic Diseases

NCT02720679

Leukocyte Disorder Bone Marrow Failure Syndromes Erythrocyte Disorder +10 more

RECRUITING

Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History

NCT06923670

Polycythemia Vera Essential Thrombocythaemia Myelofibrosis

NOT_YET_RECRUITING NA

Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders

NCT00582621

Colon Cancer Lymphoma Leukemia +2 more

RECRUITING

Genetic Analysis of Familial Melanoma

NCT00339404

Melanoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Polycythemia Vera Essential Thrombocythemia Idiopathic Myelofibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

FAMILY_BASED

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Families with 2 or more members diagnosed with polycythemia vera (PV), essential thrombocythemia (ET), PV and ET related myelofibrosis (PV-MF and ET-MF), idiopathic myelofibrosis (IM) or chronic myelogenous leukemia (CML).
* Healthy family members of subjects diagnosed with a myeloproliferative neoplasm (MPN).
* Participating subjects must be 7 years of age or older
* A written assent, parental permission or consent must be obtained prior to any study procedures being performed.

Exclusion Criteria

* Subjects who have a known acquired cause of polycythemia (increased hemoglobin/hematocrit), such as people living in high altitudes (in excess of 14,000 feet), subjects with heart disease, left to right heart shunt, severe hypoxia, cyanotic congenital heart disease, or severe pulmonary disease, will be excluded from this study, secondary forms of thrombocytosis and secondary forms of myelofibrosis.

Minimum Eligible Age

7 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No